Acting Administrator Chuck Rosenberg
DEA News:
WASHINGTON, D.C. – The U.S. Drug Enforcement Administration is proposing a reduction for controlled substances that may be manufactured in the U.S. next year by 20 percent as compared to 2017, per the proposed notice being published in the Federal Register Aug. 7, 2017 and available for public inspection today.
The DEA has proposed to reduce more commonly prescribed schedule II opioid painkillers, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine and fentanyl. Demand Read More








U.S. SENATE News:





